Understanding Tysabri and PML Risk: What Patients Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection typically emerges months to years after starting treatment, with specific risk factors influencing the timeline. Building on decades of clinical research, this page provides a clear overview of PML onset patterns, monitoring strategies, and what the science says about managing this risk.

Find Out If You Qualify for Compensation →

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals, and it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition presents with progressive neurological deficits, including cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients who received Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified thousands of reports of neurological symptoms consistent with PML, including fatigue (19,150 reports), gait disturbance (9,422 reports), balance disorder (5,621 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JC virus. The FDA-approved label includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also lists common adverse reactions such as headache, influenza-like illness, peripheral edema, and infections including sinusitis and vaginal infections (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). FAERS data show that the most frequently reported adverse events include multiple sclerosis relapse (16,691 reports), headache (9,626 reports), and asthenia (7,852 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Mechanistic Pathways Linking Tysabri to PML

The mechanistic link between Tysabri and PML involves reduced immune surveillance in the central nervous system. By blocking lymphocyte trafficking, Tysabri decreases the ability of the immune system to control JC virus replication. The virus can then reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and neurological damage. Three risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Considerations

The FDA has required a boxed warning for Tysabri since its reintroduction to the market in 2006. The warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also mandates that Tysabri be available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to educate prescribers and patients about PML risk and to monitor for early signs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions remain about whether patients and healthcare providers fully understand the magnitude of risk, particularly regarding the cumulative effect of treatment duration and prior immunosuppressant use. For patients who develop PML after Tysabri treatment, legal considerations may include whether the manufacturer provided adequate warnings about the risk and whether the patient was properly monitored. The boxed warning and TOUCH program represent regulatory efforts to mitigate risk, but individual cases may involve allegations of failure to warn, failure to monitor, or inadequate informed consent. Patients should document the timing of Tysabri infusions, any prior immunosuppressant use, and the onset of neurological symptoms. Medical records should be preserved, including MRI results, JC virus antibody testing, and cerebrospinal fluid analysis. Legal counsel experienced in pharmaceutical litigation can evaluate whether the specific circumstances of a case meet the criteria for a product liability claim.

Timeline Between Exposure and Documented Harm

The latency between Tysabri initiation and PML diagnosis varies. In clinical trials, one Crohn's disease patient developed PML after eight doses, while two multiple sclerosis patients developed PML after a median of 120 weeks of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies longer treatment duration, especially beyond two years, as a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data show that PML can occur at any time during treatment, but the risk increases with cumulative exposure. Early symptoms such as fatigue, gait disturbance, and cognitive changes may be mistaken for multiple sclerosis relapse, delaying diagnosis. Prompt recognition and withholding of Tysabri are essential to improve outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to reduced immune surveillance in the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the early symptoms of PML in Tysabri patients?

Early symptoms include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Post-marketing data show fatigue, gait disturbance, balance disorder, and cognitive disorder are commonly reported (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

What legal options are available for patients who developed PML after Tysabri?

Patients may pursue product liability claims alleging failure to warn, failure to monitor, or inadequate informed consent. It is important to document treatment history, preserve medical records, and consult an attorney experienced in pharmaceutical litigation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.